The percentage of patients with a positive immune response in the different treatment groups was: 1) RA on MTX, 42%; 2) RA on anti-TNF monotherapy, 53%; 3) RA on anti-TNF + MTX, 43%; 4) RA on other biologics (abatacept 20%, rituximab 10% and tocilizumab 50%); 5) SpA on anti-TNF monotherapy, 76%; 6) SpA on anti-TNF + MTX, 47%; and 7) SpA on NSAIDs/analgesics, 59%. The gene discussed is TNF; the disease is rheumatoid arthritis.